A5076713391- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- RNA Research and Splicing
- Epigenetics and DNA Methylation
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Chemical Reactions and Isotopes
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Circular RNAs in diseases
- Ferroptosis and cancer prognosis
- Bioinformatics and Genomic Networks
- Cancer-related molecular mechanisms research
- Estrogen and related hormone effects
- Renal and related cancers
The Open University
2022-2025
Background Aggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression via histone H3 Lysine 27 tri-methylation (H3K27me3). EZH2 encodes catalytic subunit PRC2. A recently developed nucleosome capture technology (Nu.QⓇ).measures H3K27me3 levels in biological fluids. inhibitors (EZH2i) being tested clinical trials. We hypothesize...
Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating H3K36me3 in patients treated with sorafenib. Methods: A total 80 plasma samples were histone variants ELISA. Changes from baseline to best response or progressive disease correlated patient survival. Results: higher EZH2/SETD2 ratio predicted worse...
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of (PCa), emerging from advanced treatments characterized by loss androgen receptor (AR) signaling neuroendocrine features, leading to rapid progression treatment resistance. The third symposium on treatment-induced NEPC, held 21 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united global researchers clinicians. Sponsored the Vancouver Prostate Centre (VPC), Canadian Institute Health Research, Cancer...
Background. EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods. studied expression clinical cohorts (bioinformatics). determined effect EZH2i on both cellular and cell free-H3K27me3 levels. measured effects carboplatin with/without AVPC viability (IC50). how modulate gene (RNA Seq). Results. was...
The long non-coding RNA (lncRNA), HAR1A is emerging as a putative tumour suppressor. In non-neoplastic brain cells, REST suppresses expression. gliomas acts an oncogene and potential therapeutic target. It therefore conceivable that promotes glioma progression by down-regulating . To test this hypothesis, clinical databases were analysed to study: (I) / correlation; (II) prognostic role; (III) molecular pathways associated with these genes. expression subcellular localization studied in...